

Harald M Surowy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4117435/publications.pdf>

Version: 2024-02-01

50
papers

4,419
citations

236925

25
h-index

197818

49
g-index

51
all docs

51
docs citations

51
times ranked

8320
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies. <i>Cancer Gene Therapy</i> , 2022, 29, 697-708.	4.6	10
2	Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. <i>International Journal of Cancer</i> , 2022, 150, 56-66.	5.1	2
3	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	8.2	19
4	<i>QRICH1</i> variants in Verriera-Brady syndrome delineation of the genotypic and phenotypic spectrum. <i>Clinical Genetics</i> , 2021, 99, 199-207.	2.0	5
5	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	27.0	532
6	<i>C2orf69</i> mutations disrupt mitochondrial function and cause a multisystem human disorder with recurring autoinflammation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	13
7	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
8	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
9	High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. <i>British Journal of Dermatology</i> , 2021, , .	1.5	6
10	The recurrent missense mutation p.(Arg367Trp) in <i>YARS1</i> causes a distinct neurodevelopmental phenotype. <i>Journal of Molecular Medicine</i> , 2021, 99, 1755-1768.	3.9	3
11	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
12	Profound inhibition of CD73-dependent formation of anti-inflammatory adenosine in B cells of SLE patients. <i>EBioMedicine</i> , 2021, 73, 103616.	6.1	14
13	Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells. <i>Stem Cells</i> , 2021, 39, 1270-1284.	3.2	6
14	The Macrophage Migration Inhibitory Factor (MIF) Promoter Polymorphisms (rs3063368, rs755622) Predict Acute Kidney Injury and Death after Cardiac Surgery. <i>Journal of Clinical Medicine</i> , 2020, 9, 2936.	2.4	9
15	Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study. <i>Cancer Biomarkers</i> , 2020, 28, 159-167.	1.7	7
16	Two truncating variants in <i>FANCC</i> and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	3.3	5
17	The <i>GPRC5A</i> frameshift variant c.183del is not associated with increased breast cancer risk in <i>BRCA1</i> mutation carriers. <i>International Journal of Cancer</i> , 2019, 144, 1761-1763.	5.1	2
18	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019, 48, 795-806.	1.9	81

#	ARTICLE	IF	CITATIONS
19	Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 69-82.	2.5	50
20	A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<lt;60 years) and is associated with reduced DNA repair capacity. <i>International Journal of Cancer</i> , 2018, 142, 757-768.	5.1	6
21	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	21.4	184
22	Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype. <i>Human Genetics</i> , 2017, 136, 297-305.	3.8	53
23	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
24	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
25	Identification of new TRIP12 variants and detailed clinical evaluation of individuals with non-syndromic intellectual disability with or without autism. <i>Human Genetics</i> , 2017, 136, 179-192.	3.8	43
26	Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 176-187.	5.1	104
27	Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. <i>Oncotarget</i> , 2017, 8, 54537-54547.	1.8	34
28	DNA methylation array analysis identifies breast cancer associated <i>RPTOR</i> , <i>MGRN1</i> and <i>RAPSN</i> hypomethylation in peripheral blood DNA. <i>Oncotarget</i> , 2016, 7, 64191-64202.	1.8	33
29	Blood-based DNA methylation as biomarker for breast cancer: a systematic review. <i>Clinical Epigenetics</i> , 2016, 8, 115.	4.1	121
30	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). <i>Scientific Reports</i> , 2016, 6, 32512.	3.3	19
31	<i>MCM3AP</i> and <i>POMP</i> Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child. <i>Human Mutation</i> , 2016, 37, 257-268.	2.5	18
32	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CH</i> , <i>EK</i> , <i>2</i> *1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760.	1.6	152
33	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	2.9	106
34	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016, 53, 298-309.	3.2	94
35	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	2.5	26
36	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.2	76

#	ARTICLE	IF	CITATIONS
37	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	21.4	513
38	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	2.9	91
39	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	6.3	99
40	Identification and characterization of novel associations in the <i>CASP8/ALS2CR12</i> region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
41	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	12.1	97
42	Capture and Amplification by Tailing and Switching (CATS). <i>RNA Biology</i> , 2014, 11, 817-828.	3.1	68
43	Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 163-174.	2.5	142
44	Clinical and molecular characterization of the <i>BRCA2</i> p.Asn3124Ile variant reveals substantial evidence for pathogenic significance. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 451-460.	2.5	8
45	The prostate cancer risk locus at 10q11 is associated with DNA repair capacity. <i>DNA Repair</i> , 2012, 11, 693-701.	2.8	4
46	Heritability of baseline and induced micronucleus frequencies. <i>Mutagenesis</i> , 2011, 26, 111-117.	2.6	37
47	Predisposition for <i>TMPRSS2-ERG</i> Fusion in Prostate Cancer by Variants in DNA Repair Genes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3030-3035.	2.5	51
48	Reduced DNA repair in <i>BRCA1</i> mutation carriers undetectable before onset of breast cancer?. <i>British Journal of Cancer</i> , 2007, 97, 1184-1186.	6.4	5
49	Increased Radiosensitivity as an Indicator of Genes Conferring Breast Cancer Susceptibility. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 655-660.	2.0	8
50	Germline mutations of the <i>MSR1</i> gene in prostate cancer families from Germany. <i>Human Mutation</i> , 2006, 27, 98-102.	2.5	22